Current and emerging drugs for idiopathic pulmonary fibrosis
M Gharaee-Kermani, B Hu, VJ Thannickal… - Expert opinion on …, 2007 - Taylor & Francis
Idiopathic pulmonary fibrosis is a chronic, progressive and often fatal form of interstitial lung
disease. It is characterized by injury with loss of lung epithelial cells and abnormal tissue …
disease. It is characterized by injury with loss of lung epithelial cells and abnormal tissue …
Autoimmune biomarkers, antibodies, and immunologic evaluation of the patient with fibrotic lung disease
A Tzouvelekis, T Karampitsakos… - Clinics in Chest …, 2019 - chestmed.theclinics.com
Pulmonary complications represent an important extra-articular manifestation of connective
tissue disorders (CTDs) with a negative impact on quality of life and mortality (Table 1). 1 …
tissue disorders (CTDs) with a negative impact on quality of life and mortality (Table 1). 1 …
特发性肺纤维化患者外周血单个核细胞T 淋巴细胞亚群及Th1/Th2 型细胞因子的检测
吴春风， 马忠森， 王秀丽， 杨广民， 马寅芙， 杨俊玲… - 吉林大学学报: 医学 …, 2008 - cqvip.com
目的: 通过流式细胞术检测特发性肺纤维化(IPF) 患者外周血T 淋巴细胞亚群及Th1/Th2
型细胞因子水平, 探讨其在IPF 发病机制中的作用及临床意义. 方法: 采用流式细胞术检测25 …
型细胞因子水平, 探讨其在IPF 发病机制中的作用及临床意义. 方法: 采用流式细胞术检测25 …
[PDF][PDF] 特发性肺纤维化的治疗进展
盛晓文， 胡雨奇， 崔瑷 - 精准医学杂志, 2021 - jpmed.qdu.edu.cn
目的特发性肺纤维化(IPF) 是一种慢性, 进行性, 纤维化性的间质性肺疾病, 最终导致肺功能严重
损害及患者死亡. 抗纤维化药物已在全球范围内被批准用于IPF 患者的治疗, 标志着IPF …
损害及患者死亡. 抗纤维化药物已在全球范围内被批准用于IPF 患者的治疗, 标志着IPF …
[HTML][HTML] Bleomycin induces upregulation of lysyl oxidase in cultured human fetal lung fibroblasts
L Chen, W Li, S Li, X Su, G Lin, Y Huang… - Acta Pharmacologica …, 2010 - nature.com
Aim: To investigate the mechanism of bleomycin (BLM)-induced pulmonary fibrosis.
Methods: Cultured human fetal lung fibroblast (HLF) cells were exposed to bleomycin (BLM) …
Methods: Cultured human fetal lung fibroblast (HLF) cells were exposed to bleomycin (BLM) …
[HTML][HTML] Host predisposition by endogenous Transforming Growth Factor-β1 overexpression promotes pulmonary fibrosis following bleomycin injury
Y Haider, AP Malizia, DT Keating, M Birch… - Journal of …, 2007 - Springer
Abstract Background Idiopathic Pulmonary Fibrosis (IPF) is a progressive diffuse disease
involving the lung parenchyma. Despite recent advances, the molecular mechanisms of the …
involving the lung parenchyma. Despite recent advances, the molecular mechanisms of the …
[HTML][HTML] Avances en la investigación de los mecanismos moleculares, los blancos terapéuticos y el desarrollo de fármacos para la fibrosis pulmonar idiopática
H Ma, X Wu, Y Li, Y Xia - Kompass Neumología, 2022 - karger.com
La fibrosis pulmonar idiopática (FPI) es una enfermedad pulmonar intersticial de carácter
mortal. Estudios recientes han identificado el papel clave de la interacción entre las células …
mortal. Estudios recientes han identificado el papel clave de la interacción entre las células …
Update on models of pulmonary fibrosis therapy for preclinical drug research
SA Antoniu, MRJ Kolb - Expert Opinion on Drug Discovery, 2009 - Taylor & Francis
Background: Idiopathic pulmonary fibrosis (IPF) is a disease with high morbidity and
mortality for which current medications are not effective. Therefore, identification of potential …
mortality for which current medications are not effective. Therefore, identification of potential …
干扰素及其临床应用(续) 十一Ⅱ, Ⅲ 型干扰素
张丽兰， 张丽萍 - 中华实验和临床病毒学杂志, 2008 - cqvip.com
γ 型干扰素(IFN—gamma) 同名有: 抗原诱导干扰素(Antigen-induced interferon);
免疫干扰素(Immune interferon (IIF); Ⅰ 型干扰素(Type-2 interferon); T 干扰素(Tinterferon); …
免疫干扰素(Immune interferon (IIF); Ⅰ 型干扰素(Type-2 interferon); T 干扰素(Tinterferon); …
特发性肺纤维化患者外周血T 淋巴细胞亚群及相关细胞因子的变化
刘芳， 唐婷玉， 杜坚宗， 钦光跃 - 全科医学临床与教育, 2016 - cqvip.com
目的探讨特发性肺纤维化(IPF) 患者外周血中T 淋巴细胞亚群和相关细胞因子的变化.
方法选取35 例IPF 患者(IPF 组) 和38 例健康体检人员(对照组), 分别采用流式细胞技术及酶联 …
方法选取35 例IPF 患者(IPF 组) 和38 例健康体检人员(对照组), 分别采用流式细胞技术及酶联 …